Owkin has announced its expansion into the DACH region (Germany, Austria, and Switzerland) through strategic partnerships with nine leading medical centers, including Charité – Universitätsmedizin Berlin, Universitätsspital Basel, and Technische Universität München (TUM). This move aims to leverage extensive patient data, representing 24% of outpatient cases and 15% of the total patient population in the region, to advance AI-driven precision drug discovery, development, and diagnostics.
By analyzing vast datasets from these institutions, Owkin will deploy its AI engines and diagnostic tools to improve patient outcomes in prostate cancer, MIBC, and CVD. The collaboration will focus on discovering novel biomarkers, predicting treatment responses, and developing more effective, individualized therapies. For instance, BiomarkerPlus will work with Inselspital Bern and TUM to identify prostate cancer patients likely to progress to severe disease, while TargetMatch will partner with Medizinische Universität Wien to understand treatment responses in MIBC.
Owkin's TrialPlus initiative will enhance clinical trial design for CVD through machine learning techniques in collaboration with Universitätsklinikum Leipzig. Additionally, Owkin aims to improve their MSI pre-screening tool, MSIntuit® CRC, by validating its upgraded version with diverse cohorts in collaboration with Uniklinikum Erlangen. These efforts will drive personalized treatment strategies and optimize clinical trial outcomes across multiple diseases.
Beyond these disease-specific initiatives, Owkin is expanding its MOSAIC network, which aims to build the world’s largest spatial omics dataset in oncology with 7,000 patient samples across seven cancer indications. Uniklinikum Erlangen, Charité – Universitätsmedizin Berlin, and Centre Hospitalier Universitaire Vaudois (CHUV) are new partners in this global initiative, which seeks to accelerate research across various therapeutic areas.
Click here to read the original news story.